{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-001047","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.474165+00:00","generated_at":"2026-06-06T19:22:09.480914+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ADC Therapeutics grants Redmile preemptive rights up to 20% ownership threshold","bullets":["Agreement preserves Redmile's preemptive and advance subscription rights if group holds ≤20% of share capital.","If group exceeds 20%, board must find no change-of-control intent to keep rights intact; else rights may be restricted.","Redmile caps aggregate voting rights at 15% of share capital unless otherwise mutually agreed.","Agreement terminates upon removal of 20% clauses, 5 years if ownership <20%, redomiciliation, >30% ownership, or change-of-control finding.","Redmile currently owns ~18.93% of shares and has confirmed no present intention to effect a change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-001047","json":"https://secwatch.observer/filing/0000950103-24-001047.json","markdown":"https://secwatch.observer/filing/0000950103-24-001047.md","text":"https://secwatch.observer/filing/0000950103-24-001047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324001047/0000950103-24-001047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324001047/dp205528_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:22:09.480914+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"091dd27e790c72f4be29578753c7cf2d9db99417","claim":"ADC Therapeutics SA entered into Redmile Agreement with Redmile Group, LLC (effective 2024-01-18).","evidence_excerpt":"On January 18, 2024, ADC Therapeutics SA (the “Company”) entered into an agreement (the “Redmile Agreement”) with the Redmile Group, LLC (“Redmile”) regarding preemptive rights and advance subscription rights with respect to shares of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324001047/0000950103-24-001047-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Redmile Group, LLC"},{"label":"Effective","value":"2024-01-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}